Published in Radiology on October 01, 1988
Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET | NCT03065712
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.50
Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med (2009) 1.19
Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res (2005) 1.16
Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.11
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med (2011) 1.02
Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (2000) 1.01
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol (2011) 1.01
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res (2011) 0.98
Methodology for quantitative rapid multi-tracer PET tumor characterizations. Theranostics (2013) 0.98
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands. J Med Chem (2011) 0.95
Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med (2012) 0.94
Translational molecular imaging for cancer. Cancer Imaging (2005) 0.93
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol (2007) 0.90
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol (2013) 0.87
The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS One (2015) 0.86
Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol (2015) 0.85
Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. Breast Cancer Res (2000) 0.84
Targeted functional imaging in breast cancer. Eur J Nucl Med Mol Imaging (2007) 0.84
Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol (2011) 0.83
Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor. Nucl Med Biol (2007) 0.81
Preliminary in vivo breast vibro-acoustography results with a quasi-2-d array transducer: a step forward. Ultrasound Med Biol (2014) 0.80
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med (2013) 0.79
Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging. Curr Breast Cancer Rep (2011) 0.79
Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res (2008) 0.79
Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med (2016) 0.77
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. Theranostics (2016) 0.76
PET Tracers for Clinical Imaging of Breast Cancer. J Oncol (2012) 0.76
Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs (2003) 0.76
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Des Devel Ther (2015) 0.75
Breast Cancer Treatment in the Era of Molecular Imaging. Breast Care (Basel) (2008) 0.75
Precision Medicine and PET/Computed Tomography: Challenges and Implementation. PET Clin (2016) 0.75
Review: Receptor Targeted Nuclear Imaging of Breast Cancer. Int J Mol Sci (2017) 0.75
Development of Companion Diagnostics. Semin Nucl Med (2016) 0.75
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res (2016) 0.75
Reduced beta adrenoceptor density in vivo in human lung tumours: a preliminary study with positron emission tomography. Thorax (1996) 0.75
Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw (2016) 0.75
Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status. Front Oncol (2016) 0.75
A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Sci Rep (2017) 0.75
Can (18)F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor-positive Breast Cancer Patient: A Prospective Comparative Study with (18)F-Fluorodeoxyglucose Positron Emission Tomography? World J Nucl Med (2017) 0.75
Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design. Acad Radiol (2017) 0.75
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A (1986) 4.51
Neural activity relating to generation and representation of galvanic skin conductance responses: a functional magnetic resonance imaging study. J Neurosci (2000) 3.49
Neural activity in the human brain relating to uncertainty and arousal during anticipation. Neuron (2001) 3.49
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem (2000) 3.34
Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol (1997) 3.25
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Cerebral correlates of autonomic cardiovascular arousal: a functional neuroimaging investigation in humans. J Physiol (2000) 2.72
International standards to document remaining autonomic function after spinal cord injury. Spinal Cord (2008) 2.65
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg (2001) 2.40
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol (2001) 2.20
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2001) 2.15
A gallium-68 radiopharmaceutical that is retained in myocardium: 68Ga[(4,6-MeO2sal)2BAPEN]+. J Nucl Med (1993) 2.06
FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol (2000) 1.96
Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev (1999) 1.93
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology (1999) 1.93
Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol (1983) 1.88
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med (1982) 1.85
The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids (1997) 1.80
Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol (1997) 1.77
Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med (1990) 1.77
Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science (1994) 1.73
Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res (2000) 1.69
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry (2001) 1.68
Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry (1973) 1.67
Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet (1997) 1.65
Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. J Nucl Med (2000) 1.65
Evidence that phospholipase A2 activity is required for Golgi complex and trans Golgi network membrane tubulation. Proc Natl Acad Sci U S A (1998) 1.65
Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol (2001) 1.64
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med (1999) 1.62
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
Neuroanatomical basis for first- and second-order representations of bodily states. Nat Neurosci (2001) 1.61
Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med (1993) 1.56
Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med (1983) 1.55
The prevalence and association of neck (coat-hanger) pain and orthostatic (postural) hypotension in human spinal cord injury. Spinal Cord (2002) 1.55
Physiological assessment of aspects of autonomic function in patients with secondary progressive multiple sclerosis. J Neurol (1993) 1.52
Radiation synovectomy revisited. Eur J Nucl Med (1993) 1.52
The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol (1998) 1.52
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med (2001) 1.51
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med (1999) 1.49
Organisation of the sympathetic skin response in spinal cord injury. J Neurol Neurosurg Psychiatry (2002) 1.49
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology (1987) 1.49
Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. Am J Physiol (1976) 1.48
In vivo comparison of copper blood-pool agents: potential radiopharmaceuticals for use with copper-62. J Nucl Med (1991) 1.46
Ventilation-perfusion studies in suspected pulmonary embolism. AJR Am J Roentgenol (1979) 1.45
Elevations of CK-MB following pulmonary embolism. A manifestation of occult right ventricular infarction. Chest (1992) 1.44
New autonomic and sensory neuropathy with loss of adrenergic sympathetic function and sensory neuropeptides. Lancet (1991) 1.43
In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol (1990) 1.42
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem (1982) 1.41
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.40
Cardiovascular, autonomic, and plasma catecholamine responses in unilateral and bilateral carotid artery stenosis. J Neurol Neurosurg Psychiatry (1999) 1.40
Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res (1979) 1.39
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol (2001) 1.39
Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol (1999) 1.39
Clinical Autonomic Research in the 1990s. Clin Auton Res (1991) 1.39
EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol (2006) 1.37
Zearalenones: characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. Endocrinology (1979) 1.36
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res (1996) 1.35
Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med (1995) 1.34
Diffusible Factors Essential for Epidermal Cell Redifferentiaion in Catharanthus roseus. Science (1989) 1.33
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg (1998) 1.30
Unexplained syncope--is screening for carotid sinus hypersensitivity indicated in all patients aged >40 years? J Neurol Neurosurg Psychiatry (2006) 1.30
Copper-64-labeled antibodies for PET imaging. J Nucl Med (1992) 1.29
Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res (2000) 1.29
Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J Med Chem (1994) 1.29
Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology (2002) 1.26
Plasma catecholamines, plasma renin activity and plasma aldosterone in tetraplegic man, horizontal and tilted. Clin Sci Mol Med (1975) 1.26
Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology (2009) 1.26
Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst (1998) 1.25
Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum (2000) 1.25
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med (2001) 1.25
Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology (1993) 1.24
Quantification of regional myocardial blood flow in vivo with H215O. Circulation (1984) 1.24
Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. J Biol Chem (1983) 1.24